Overactive bladder (OAB) is defined by symptoms of urinary urgency, usually accompanied by increased daytime frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology. 1, 2 Urgency urinary incontinence affects approximately one third of all OAB cases. 3 Compared with continent ("dry") OAB patients, incontinent ("wet") OAB patients experience greatly diminished quality of life (QoL), reporting higher rates of depression, psychological and emotional distress, and social isolation. 4, 5 The severity of urgency urinary incontinence is strongly correlated with reductions in QoL, 6 suggesting that incontinent OAB patients who are refractory to treatment are likely to be extremely dissatisfied with their QoL. Daily activities are often severely disrupted, and incontinent patients are more likely to require assistance with daily activities, placing an additional financial burden on society. 7 OAB patients are more likely to seek treatment once symptoms affect health-related quality of life (HRQoL), 8 and to persist with treatment if HRQoL improves. 9 Objective efficacy assessments are essential in OAB trials. However, the greatest treatment benefit experienced by patients is likely to be related to improvements in QoL. It is, therefore, equally important to assess subjective, patient-reported outcomes (PROs) including HRQoL and perception of symptoms, and how these correlate with clinically meaningful improvements in OAB symptoms. Bladder health questionnaires such as the overactive bladder questionnaire (OAB-q) assess overall HRQoL, symptom bother and domains related to daily activities, social functioning and sleep. Understanding the impact of OAB symptoms and their treatment from the perspective of the patient, in addition to BESIDE Responder 3rd draft February 2016 5 clinically relevant improvements in symptoms based on the micturition diary, will improve treatment satisfaction and the effective management of OAB symptoms.
Antimuscarinics (eg solifenacin) and the β3-adrenoceptor agonist, mirabegron, are the oral pharmacotherapies for treating OAB. Both classes of drugs exhibit similar efficacy, but unlike antimuscarinics, mirabegron is not associated with anticholinergic side effects. [10] [11] [12] Patients are usually initiated on an antimuscarinic, with dose escalation if symptom improvement is inadequate. This may increase the anticholinergic burden, the risk of bothersome side effects and treatment discontinuation. 13 Other patients may be switched to an alternative antimuscarinic or mirabegron. Those who do not meet their treatment goal with medical therapy are potential candidates for intravesical onabotulinumtoxinA, an invasive treatment that may require intermittent self-catheterization and is often characterized by a fluctuating response over time, and urinary tract infection. 14 Other alternatives include percutaneous tibial nerve stimulation and sacral nerve stimulation. 15, 16 The BESIDE study (NCT01908829) demonstrated a significant benefit with 12 weeks' solifenacin 5 mg plus add-on mirabegron in incontinent OAB patients vs solifenacin 5 and 10 mg monotherapy in terms of improving daily incontinence, micturition frequency and urgency. Furthermore, the safety profile of the combination was similar to that of mirabegron or solifenacin monotherapy. 17 This analysis assessed whether improvements in objective endpoints translated into improvements in subjective HRQoL endpoints. PROs were investigated using bladder health questionnaires to evaluate HRQoL, treatment satisfaction and each patient's perception of their bladder condition. In addition, responder analyses assessed the proportion of patients who achieved clinically meaningful improvements in incontinence (asymptomatic ["dry"] or BESIDE Responder 3rd draft February 2016 6 ≥50% reduction in incontinence episodes) and micturition frequency (<8 micturitions/24 hours) at the end of treatment (EoT). The objectives were to compare combination (solifenacin 5 mg/mirabegron 50 mg) with solifenacin 5 and 10 mg in terms of PROs related to HRQoL, and to explore the relationship between clinically relevant improvements in PROs and in micturition frequency and incontinence.
METHODS

Study Design and Patient Demographics
In this randomized, double-blind, parallel-group, multicenter phase IIIb study, patients ≥18 years of age, with OAB for ≥3 months, including an average of ≥2 incontinence episodes/24 hours entered a 2-week screening/wash-out period to remove the effects of previous OAB medication and familiarize with the patient-recorded electronic micturition diary. After 4 weeks of single-blind daily solifenacin 5 mg, patients remaining incontinent (≥1 episode during the 3-day diary) at baseline, were eligible for double-blind treatment (Fig. 1) .
Patients who satisfied inclusion and did not meet exclusion criteria (Appendix A1) were randomized 1:1:1 to 12 weeks of double-blind daily treatment with combination (solifenacin 5 mg plus mirabegron 25 mg for first 4 weeks, increasing to mirabegron 50 mg for the remaining 8 weeks), solifenacin 5 or 10 mg (Appendix A2).
Patient-reported Outcomes
QoL was assessed using the OAB-q (Symptom Bother score, total HRQoL and subscales of Coping [toilet mapping], Concern, Sleep and Social Interaction), the patient perception of bladder condition (PPBC) questionnaire, and the treatment satisfaction-visual analog scale (TS-VAS) (Table 1) ; the OAB-q and PPBC have been validated in OAB trials. 18-20 Questionnaire scores were recorded by the patient using an electronic handheld device at baseline, weeks 4, 8 and 12/EoT. The primary analysis was change from baseline to EoT in scores for Symptom Bother, HRQoL and subscales, TS-VAS and PPBC.
Responder Analyses
Seven responder analyses, 3 based on objective efficacy outcomes for incontinence and micturition frequency, and 4 based on PROs related to HRQoL and PPBC, were selected for inclusion. Based on the 3-day micturition diary prior to each study visit, efficacy responders were defined as patients with ≥50% decrease from baseline in mean number of incontinence episodes/24 hours at EoT, zero incontinence episodes at EoT ("dry" OAB patients), and ≥8 micturitions/24 hours at baseline and <8 micturitions/24 hours at EoT. PRO responders were defined as a patient who achieved a change from baseline to EoT that exceeded the minimal important difference (MID) in the OAB-q or PPBC. The MID is defined as "the smallest difference in score in the domain of interest that patients perceive as beneficial and which would mandate, in the absence of troublesome side effects and excessive costs, a change in patient management", 21 and equates to 10 points for the total OAB-q and its subscales (HRQoL and Symptom Bother) 22-24 and a 1-point improvement in PPBC. 20 Based on the change from baseline to EoT, PRO responders were those patients with: ≥10-point improvement in OAB-q Symptom Bother; ≥10-point improvement in OAB-q 
RESULTS
Patient Demographics
Overall 2,174 patients were randomized to combination (n=727), solifenacin 5 mg (n=728) or solifenacin 10 mg (n=719) (Fig. 2) . Patient demographics and baseline characteristics were similar across groups and included a median age 59.0 years, mean number of incontinence episodes/24 hours >3, mean number of micturitions/24 hours >8, and OAB-q scores indicative of significantly impaired QoL (Symptom Bother score >50 [scores range from 0 to 100; higher scores indicate greater symptom bother] and total HRQoL score ~60
[scores range from 0 to 100; higher scores indicate better QoL]) ( Table 2) .
Patient-reported Outcomes
Combination demonstrated superiority over solifenacin 5 and 10 mg for change from baseline to EoT in the Symptom Bother score, total HRQoL and subscales (with the exception of Sleep vs solifenacin 5 mg) and the PPBC (Fig. 3) 
Efficacy and PRO Responder Analyses
At EoT, there were statistically significant differences in favor of combination vs both solifenacin 5 and 10 mg for the proportion of responders who became continent, and vs solifenacin 5 mg for those with a ≥50% decrease in incontinence episodes/24 hours and normalization of micturition frequency (<8 micturitions/24 hours) ( Fig. 4A-C) . Odds ratios for combination treatment vs solifenacin 5 and 10 mg, respectively, indicated that patients receiving combination were 47% (OR 1.47; 95% CI 1.17, 1.84; p=0.001) and 28% (OR 1.28; 95% CI 1.02, 1.61; p=0.033) more likely to achieve zero incontinence, 51% and 25% more likely to achieve a ≥50% reduction in incontinence episodes/24 hours and 29% and 12% more likely to achieve normalization of micturition frequency. There were statistically BESIDE Responder 3rd draft February 2016 11 significant odds ratios in favor of combination vs solifenacin 5 and 10 mg in the proportion of responders with ≥10-point improvement in Symptom Bother score, the total HRQoL and a major (≥2 point) improvement in PPBC ( Fig. 4D- 
G). The odds of achieving MIDs in Symptom
Bother, total HRQoL and a major improvement in PPBC, respectively, was 75%, 50% and 55% higher with combination vs solifenacin 5 mg, and 54%, 47% and 29% higher vs solifenacin 10 mg.
Exploratory Variables: Double and Triple Responder Analyses
At EoT, statistically significant improvements were demonstrated for all 5 exploratory variables in favor of the combination group vs solifenacin 5 mg, and for 3 of the 5 variables vs solifenacin 10 mg (Table 3) . Compared with solifenacin 5 and 10 mg, respectively, patients on combination were 73% and 26% more likely to simultaneously achieve a ≥50% reduction in incontinence episodes/24 hours, ≥10-point improvement in Symptom Bother score, and ≥1-point improvement in PPBC, and 55% and 39% more likely to achieve this triple responder status but with a ≥10-point improvement in total HRQoL rather than Symptom Bother.
DISCUSSION
QoL encompasses socio-demographic, clinical, psychological and social factors highlighting the importance of assessing the patients' perceptions of treatment on their OAB symptoms.
OAB patients with refractory incontinence are more likely to have a poor QoL and negative experience of their treatment than "dry" OAB patients. 4 The validity of the bladder health questionnaires, OAB-q and PPBC, and the clinical utility of the respective MIDs have been confirmed in previous studies and demonstrate a strong correlation with symptom improvement based on bladder diary assessment. [18] [19] [20] Responder analyses in this study identified the proportion of patients achieving clinically meaningful improvements in subjective measures of HRQoL and treatment perception, and objective efficacy outcomes, individually or combined (double/triple responders).
In refractory incontinent OAB patients, combination significantly improved Symptom Bother, total HRQoL and its subscales vs solifenacin monotherapy, with the exception of the HRQoL subscale of "Sleep" vs solifenacin 5 mg. This may be related to the reduced treatment effect with combination and solifenacin monotherapy on nocturia, as previously reported. 17 Similar benefits were observed with combination vs solifenacin 5 mg for treatment satisfaction and patients' perception of major improvements in their condition.
A higher proportion of patients on combination compared with solifenacin 5 and 10 mg achieved clinically meaningful improvements in efficacy and PRO responder analyses, which was significant in most cases. Compared with solifenacin 5 mg, patients receiving combination were approximately 50% more likely to achieve full continence or a ≥50% reduction in incontinence. This benefit was less pronounced for micturition normalization, Marcus J. Drake has received consultancy and speaker fees from Allergan, Astellas, and Ferring, and received research fees from Allergan, Astellas, Ferring, and Vysera.
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[1] Only patients who used previous OAB medications [2] Patients could have discontinued previous OAB medications for several reasons Table 3 . Double responder analyses at EoT: 50% reduction in mean number of incontinence episodes/24 hours and improvement ≥10 points on the Symptom Bother Scale (OAB-q); 50% reduction in mean number of incontinence episodes/24 hours and ≥ 10-point improvement on
HRQoL Total score (OAB-q); 50% reduction in mean number of incontinence episodes/24 hours and ≥ 1-point improvement in PPBC; and triple responder analyses at EoT: 50% reduction in mean number of incontinence episodes/24 hours, improvement by ≥10 points on the Symptom
Bother Scale (OAB-q) and ≥1-point improvement in PPBC; 50% reduction in mean number of incontinence episodes/24 hours, improvement by ≥10 points on the HRQoL Total Score (OAB-q) and ≥1-point improvement in PPBC. 
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